Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Bill Thelin has signed on to serve as Altis Biosystems’ new chief scientific officer. Prior to joining Altis, Thelin was vice president of research at Parion Sciences.
Commercial stage biopharmaceutical company Amryt has named Sheila Frame the president of Americas. Frame was most recently the vice president and global disease lead at Novartis Oncology.
Laurence Blumberg has been named president and CEO of Arch Oncology. Blumberg comes to Arch from Syntimmune, where he served as founding CEO and director.
Howard Federoff will take the helm at Brooklyn ImmunoTherapeutics as its newest CEO. Previously, Federoff was the CEO of UCI Health.
John Robinson has been named chief scientific officer of Cogent Biosciences’ newly formed Cogent Research Team. Robinson was most recently the vice president of medicinal chemistry at Pfizer.
Sumit Aggarwal, the former president and CEO of Zikani, has been appointed CEO of Eloxx Pharmaceuticals. Vijay Modur, another Zikani veteran who served as the company’s chief scientific and medical officer, has been named head of R&D at Eloxx.
Evonetix has appointed Michael Daniels to head of product management. Daniels was previously the director of marketing and product management at Arcis Biotechnology.
William Kennedy, former vice president of development at Calcilytix, has been named senior vice president of clinical at Excision BioTherapeutics.
Cyril Konto has been named chief medical officer of biotech company Ichnos Sciences. Prior to this appointment, Konto served as vice president of clinical development at Allogene Therapeutics.
IM Therapeutics has named David Alleva the company’s new vice president of immunology. Alleva previously served as executive director of immunotherapeutics at Akston Biosciences.
ImmuneID has appointed Annalisa D’Andrea to president and chief scientific officer. D’Andrea was previously the chief scientific officer of Kiniksa Pharmaceuticals.
Grazia Piizzi has been named chief scientific officer of Juvenescence. Formerly, Piizzi was the senior vice president of small molecules R&D and head of inflammation at Cygnal Therapeutics.
Patrick Lucy, former president and chief operating officer of Lykan Bioscience, has been promoted to president and CEO of the company.
Pamela Tenaerts has been hired by Medable to serve as the company’s chief scientific officer. Prior to this appointment, Tenaerts was executive director of Duke University’s Clinical Trials Transformation Initiative.
Overland ADCT BioPharma
Overland ADCT BioPharma has appointed Eric Koo to lead the company as its newest CEO. Koo comes to Overland from Takeda China, where he served as vice president and head of the oncology business unit.
Late-stage clinical company Prothena has found its newest chief medical officer in Hideki Garren, former vice president and global head of neuroimmunology at F. Hoffmann-La Roche.
Richard Bryce, former chief medical and scientific officer of Puma Biotechnology, has been named executive vice president and chief medical officer of Rain Therapeutics.
Martin Kessler has been named CEO of Rentschler Biopharma’s U.S. subsidiary. Kessler most recently served as an associate partner at McKinsey & Co.
David Davidson, former chief medical officer of bluebird bio, has been named chief medical and development officer of Tessera Therapeutics. Tessera also recently appointed Hari Pujar to chief operating officer and Lin Guey to senior vice president of rare diseases program strategy and operations. Pujar is the former chief technology officer at Spark Therapeutics, and Guey most recently served as the vice president of program and portfolio strategy at Xilio Therapeutics.
Tyme Technologies has named Jan Van Tornout as its newest chief medical officer. Van Tornout was previously the senior vice president and head of oncology at Natera.